Peterlik Daniel, Flor Peter J, Uschold-Schmidt Nicole
Faculty of Biology and Preclinical Medicine, University of Regensburg, D-93053 Regensburg, Germany.
Curr Neuropharmacol. 2016;14(5):514-39. doi: 10.2174/1570159x13666150515234920.
Chronic stress-related psychiatric conditions such as anxiety, depression, and alcohol abuse are an enormous public health concern. The etiology of these pathologies is complex, with psychosocial stressors being among the most frequently discussed risk factors. The brain glutamatergic neurotransmitter system has often been found involved in behaviors and pathophysiologies resulting from acute stress and fear. Despite this, relatively little is known about the role of glutamatergic system components in chronic psychosocial stress, neither in rodents nor in humans. Recently, drug discovery efforts at the metabotropic receptor subtypes of the glutamatergic system (mGlu1-8 receptors) led to the identification of pharmacological tools with emerging potential in psychiatric conditions. But again, the contribution of individual mGlu subtypes to the manifestation of physiological, molecular, and behavioral consequences of chronic psychosocial stress remains still largely unaddressed. The current review will describe animal models typically used to analyze acute and particularly chronic stress conditions, including models of psychosocial stress, and there we will discuss the emerging roles for mGlu receptor subtypes. Indeed, accumulating evidence indicates relevance and potential therapeutic usefulness of mGlu2/3 ligands and mGlu5 receptor antagonists in chronic stress-related disorders. In addition, a role for further mechanisms, e.g. mGlu7-selective compounds, is beginning to emerge. These mechanisms are important to be analyzed in chronic psychosocial stress paradigms, e.g. in the chronic subordinate colony housing (CSC) model. We summarize the early results and discuss necessary future investigations, especially for mGlu5 and mGlu7 receptor blockers, which might serve to suggest improved therapeutic strategies to treat stress-related disorders.
慢性应激相关的精神疾病,如焦虑、抑郁和酒精滥用,是一个巨大的公共卫生问题。这些疾病的病因复杂,社会心理应激源是最常被讨论的风险因素之一。大脑谷氨酸能神经递质系统经常被发现参与急性应激和恐惧所导致的行为及病理生理过程。尽管如此,关于谷氨酸能系统成分在慢性社会心理应激中的作用,无论是在啮齿动物还是人类中,人们了解得都相对较少。最近,针对谷氨酸能系统的代谢型受体亚型(mGlu1 - 8受体)的药物研发工作,导致了一些在精神疾病方面具有新潜力的药理学工具的发现。但是,单个mGlu亚型对慢性社会心理应激的生理、分子和行为后果表现的贡献,在很大程度上仍未得到解决。本综述将描述通常用于分析急性特别是慢性应激状况的动物模型,包括社会心理应激模型,并且我们将在那里讨论mGlu受体亚型的新作用。事实上,越来越多的证据表明mGlu2/3配体和mGlu5受体拮抗剂在慢性应激相关疾病中的相关性和潜在治疗用途。此外,其他机制的作用,例如mGlu7选择性化合物的作用,也开始显现。这些机制在慢性社会心理应激范式中,例如在慢性从属群体饲养(CSC)模型中,进行分析很重要。我们总结了早期结果,并讨论了未来必要的研究,特别是针对mGlu5和mGlu7受体阻滞剂的研究,这可能有助于提出改善治疗应激相关疾病的策略。